UNSPSC 51312504: Tiacrilast

This classification denotes a histamine-1 receptor antagonist with the molecular formula C12H10N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74L3DXN051, chemically known as 2-propenoic acid, 3-(6-(methylthio)-4-oxo-3(4h)-quinazolinyl)-, (e)- but generally known as tiacrilast, which bears US NIH Compound Identifier 6435375. European Medicines Agency schedules Tiacrilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10997MIG.

UNSPSC 51312504 Tiacrilast, a Commodity code, does not accurately reflect the state and local pharmaceutical procurement activity tagged under it. The recent opportunities posted under this code involve naloxone dispensing and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which align with tiacrilast (a mast-cell stabilizer ophthalmic agent). The code shows a labeling mismatch rather than coherent procurement activity in a single product category. State and local buyers sourcing under this designation are pursuing broader pharmaceutical supply agreements, drug abuse mitigation resources, and multi-state cooperative purchasing arrangements for pharmacy benefit programs, not specialized pharmaceutical compounds by brand or therapeutic class.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration). Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with proposals due March 26, 2026. The geographic footprint spans Florida, Texas, Minnesota, and Oregon. Given the code's classification mismatch with the opportunities posted against it, this code does not represent a reliable source of targeted procurement signals for vendors in any single pharmaceutical market segment.